| ETHICS EDUCATION |
|
| Year : 2020 | Volume
: 11
| Issue : 4 | Page : 174-177 |
|
|
Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness
Arun Bhatt
Consultant – Clinical Research and Drug Development, Mumbai, Maharashtra, India
Correspondence Address:
Dr. Arun Bhatt
303-4, Dheeraj Valley 3/C, Mohan Gokhale Road, Goregaon East, Mumbai - 400 063, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/picr.PICR_271_20
|
|
|
Obtaining informed consent from vulnerable patients participating in clinical trials of investigational therapies for COVID-19 is a major ethical challenge. Ethical and operational considerations – voluntariness, waiver, timing, time, documentation, and responsibilities of the sponsor, the investigator, and the ethics committee – are discussed briefly.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
